News | February 11, 2026
Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The revenues this quarter are in line with the outlook we envisaged for the year
HCG clinicians contributing to one of the largest bodies of oncology research from India
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Inspection included drug device combinations covering our recent filing in nasal sprays domain
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Subscribe To Our Newsletter & Stay Updated
